Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Biotech Stocks to Buy Under $10

Page 1 of 9

In this article, we will be taking a look at the 10 Best Biotech Stocks to Buy Under $10.

The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC’s “Squawk Box” on July 25 to discuss various topics, including the current status of the biotech industry and what to expect from the earnings season.

She said that the biotech and healthcare industries have experienced several years of negative earnings revision cycles, and she wants to see these businesses now hitting the figures.

They have begun to show some steadiness, Richter continued, and Q2 is usually a stronger quarter. As a result, some biotech businesses in the sector could produce impressive financial outcomes.

According to the expert, launches and pipelines beyond statistics are two additional elements to consider in the sector.

She will continue to keep an eye on the several medicine launches that have occurred this year. Speaking of pipelines that go beyond statistics, she said that pain and Alzheimer’s disease have begun to receive attention this season.

With this in mind, let’s now take a look at the 10 best biotech stocks to buy under $10.  

A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague.

Our Methodology 

For our methodology, we screened stocks with a share price below $10 and ranked them according to the number of hedge fund holders as of Q2 2025, based on data from the Insider Monkey database. Additionally, we included the share price as of the most recent closing (21 August) in the subheadings for clarity.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 10 best biotech stocks to buy under $10.  

10. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 14 

Share Price: $2.26 

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology company developing next-generation immunotherapies and cell therapies to treat cancer and infectious diseases, and is among the best biotech stocks. Its lead product, ANKTIVA, is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer (NMIBC), designed to activate NK cells, T cells, and memory T cells for durable disease control.

In June 2025, the FDA granted Expanded Access authorization for ImmunityBio, Inc. (NASDAQ:IBRX)’s Cancer BioShield™ platform, anchored by ANKTIVA, to treat lymphopenia in patients with relapsed or refractory solid tumors. These patients typically have critically low lymphocyte counts after standard treatments like chemotherapy or radiation. Data presented at the 2025 ASCO Annual Meeting showed that restoring lymphocytes in this group significantly prolongs survival, highlighting the company’s potential to address one of the most dangerous side effects of cancer therapy.

The business is also broadening its pipeline. In August 2025, it launched a Phase 2 trial of ANKTIVA for Long COVID, exploring immune modulation for post-infectious chronic disease. Additionally, the corporation initiated ResQ201A, a randomized trial combining N-803 (an interleukin-15 superagonist) with a PD-1 inhibitor for second-line non-small cell lung cancer, with plans for global expansion.

For papillary-only NMIBC, the FDA previously issued a Refuse-to-File letter on a supplemental BLA, but ImmunityBio, Inc. (NASDAQ:IBRX) is resubmitting updated long-term trial data showing encouraging outcomes with ANKTIVA plus BCG. The company is also engaging with regulators to update clinical guidelines that could expand access for more bladder cancer patients.

9. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 17 

Share Price: $4.17 

AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company using its antibody discovery platform to develop therapies for cancer, autoimmune, metabolic, and endocrine disorders. Long recognized for industry partnerships, the company is now advancing into clinical development with proprietary assets.

In August 2025, AbCellera Biologics Inc. (NASDAQ:ABCL) dosed the first participants in a Phase 1 trial of ABCL635, a non-hormonal antibody therapy targeting the neurokinin 3 receptor (NK3R) for vasomotor symptoms of menopause, such as hot flashes. Current treatments are largely hormone-based, making this candidate a potential breakthrough for millions of women seeking safer, long-acting alternatives. The trial will evaluate safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women.

AbCellera Biologics Inc. (NASDAQ:ABCL) also received Health Canada approval to begin a Phase 1 trial of ABCL575, an antibody antagonist of OX40 ligand (OX40L) for atopic dermatitis and other inflammatory conditions. Preclinical data suggest it could inhibit T cell–mediated inflammation with extended dosing intervals, potentially improving efficacy and convenience for patients.

Page 1 of 9

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…